Conference Day One
8:00 am Light Breakfast & Check-In
8:50 am Chair’s Opening Remarks
Enhancing Mass Spectrometry Through Optimized DIA & TMT Workflows to Balance Speed & Sensitivity for Reliable Workflows
9:00 am Using Proteomics to Accelerate Drug Discovery in Targeted Protein Degradation
Synopsis
- Application of mass spectrometry-based proteomics in TPD development process, from target identification and validation to protein-protein interaction
- Proteomics strategies to dissect protein degradation mechanism
- Optimizing LC-MS/MS methods to maximize throughput and sensitivity while balancing quality and data confidence
- Streamlining data analysis to increase productivity and discovery of actionable drug targets
9:30 am Optimizing Data Independent Acquisition for Comprehensive Target Discovery & Occupancy Assays with Higher Reproducibility
Synopsis
- Switching from a TMT focused approach to DIA for more reliable data acquisition
- Ensuring comprehensive coverage of the screening pool for covalent drug discovery using DIA approaches
- Enabling higher throughout DIA-based target occupancy assays to advance covalent drug development
10:00 am High-Throughput & Accurate Multiplexed Approach for Overcoming Bottlenecks in Large-Scale Proteomics
Synopsis
- Deeply profiled over 300 tissue samples with TMT-based proteomics, completing sample preparation in under two weeks
- Established high-throughput analysis with minimal sample-to-sample variability through an in-house developed robust, automated multiplexed proteomics platform
- Achieved high quantification accuracy by utilizing ion data and a specific experimental design for precise protein quantification across numerous samples and acquisition runs
10:30 am Morning Break & Speed Networking
Optimizing Proteomics Approaches for Covalent Drug Discovery: Addressing Specificity, Probe Development, & Metabolite Challenges
11:30 am Covalent Drug Discovery by Chemoproteomics: Deconvolution of Phenotypic Screening Hits Through IMTAC Proteome-Wide, Live-Cell Screening
Synopsis
- Discussing the advantages of IMTAC proteome-wide, live-cell screening to further drug discovery efforts
- Identification of novel targets with the potential to overcome acquired chemotherapy resistance in high-grade serous ovarian cancer
12:00 pm Advancing Histidine, Tyrosine and Lysine (HYK) Covalent Probes in Mass Spectrometry
Synopsis
- Using mass spectrometry to optimize probes for covalent targeting of HYK residues that can monitor novel pockets across the proteome
- Developing methods for robust high-throughput mass spec analysis of HYK probe-labeled peptides
- Leveraging the HYKU platform to support covalent and non-covalent drug discovery programs
12:30 pm Harnessing Proteomics & Deep Learning Approaches to Enable Covalent Drug Discovery
Synopsis
- Systematic and proteome-wide druggability of proteins in the native setting is synergistically enabled by the combination of Covalency and Mass Spectrometry
- Deep Learning improves deconvolution of Mass Spectrometry-based Proteomics data and boosts the sequence coverage of Covalent Chemoproteomics
- Structural Mass Spectrometry combined with machine learning for improved prediction of ligandability of residues, protein structure, and topology
1:00 pm Lunch Break & Networking
Unveiling Protein-Protein Interactions: Advancing Protein Complex Studies Through Translational Proteomic for Informing Drug Development
2:00 pm Decoding Protein Protein Interactions: Insights from Affinity Purification Mass Spectrometry and Convergent Network Analysis
Synopsis
- Elucidation of novel drug targets using network analysis and APMS
- The investigation of differential protein-protein interaction (PPI) networks in response to drugs
- Leveraging complementary MS based proteomics approaches to gain further insight into PPIs and network biology
2:30 pm Deconvolution of Protein Complexes to Understand Mechanism of Action for Small Molecule Drugs
Synopsis
- Profiling cellular target engagement of small molecule drugs
- Identifying target protein interactors and complexation states
- Determining specific target protein complexes engaged by small molecule drugs
3:00 pm Afternoon Networking Break & Poster Session
Advancing Proteomic Approaches for the Discovery & Development of Proximity-Based Therapeutics for Improved Molecular Glue Degraders
4:00 pm Advancements in Target Discovery & Chemoproteomics with a New Induced Proximity Platform
Synopsis
- Overview of the newly established platform at Fischer Labs, highlighting its capabilities and applications
- Insights into the identification of new targets for glue compounds and its potential for use in degrader technologies
- Utilization of the platform for comprehensive and unbiased chemoproteomic screening to uncover novel targets
4:30 pm Leveraging Proteomics to Accelerate Target Identification for Molecular Glue Degraders
Synopsis
- Developing proteomics platform for molecular glue degraders
- Increasing Proteomics throughput using DIA approach to accelerate target identification
- Combining proteomics, structural biology, and proximity labelling techniques to efficiently validate and characterize novel targets.